{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T22:29:46Z","timestamp":1767911386402,"version":"3.49.0"},"reference-count":32,"publisher":"Duke University Press","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In 2022, 48.7 million people in the United States (17.3% of the population aged 12 or older) met the criteria for substance use disorder (SUD). Nearly 40% of people with opioid use disorder (OUD) are Medicaid recipients, making Medicaid the largest single source of OUD treatment insurance coverage. Despite this crucial importance, two major barriers to expanding access to treatment for persons with SUD are baked into the program: the institutions for mental diseases (IMD) exclusion and the Medicaid inmate exclusion. This article first provides a timeline of these two waiver reforms to illustrate the variation in waivers over time and across states. Then it assesses the evidence to date on how well the SUD waivers are working to accomplish these goals in states that have adopted them. This review will focus on the SUD waivers that address the IMD exclusion, because the Medicaid inmate exclusion waivers are too new for any systematic evidence. It will then consider outstanding implementation challenges and policy risks associated with the IMD and Medicaid inmate exclusion waivers, and it will conclude by considering challenges that these waivers do not address and that therefore demand particular attention to properly serve persons living with SUD.<\/jats:p>","DOI":"10.1215\/03616878-12166733","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T03:35:10Z","timestamp":1754883310000},"page":"83-100","source":"Crossref","is-referenced-by-count":0,"title":["Section 1115 Substance Use Disorder Waivers: Opportunities and Limitations"],"prefix":"10.1215","volume":"51","author":[{"given":"Thomas","family":"Statchen","sequence":"first","affiliation":[{"name":"University of Chicago"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold","family":"Pollack","sequence":"additional","affiliation":[{"name":"University of Chicago"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda J.","family":"Abraham","sequence":"additional","affiliation":[{"name":"University of Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina M.","family":"Andrews","sequence":"additional","affiliation":[{"name":"University of South Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen M.","family":"Grogan","sequence":"additional","affiliation":[{"name":"University of Chicago"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"73","published-online":{"date-parts":[[2026,2,1]]},"reference":[{"key":"2026010812401125400_jhppl12166733C1","doi-asserted-by":"crossref","DOI":"10.1016\/j.josat.2023.209034","article-title":"Use of Residential Opioid Use Disorder Treatment Among Medicaid Enrollees in Nine States","volume":"149","author":"Allen","year":"2023","journal-title":"Journal of Substance Use and Addiction Treatment"},{"key":"2026010812401125400_jhppl12166733C2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2019.04.002","article-title":"Medicaid Coverage in Substance Use Disorder Treatment After the Affordable Care Act","volume":"102","author":"Andrews","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"key":"2026010812401125400_jhppl12166733C3","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.109847","article-title":"The Effect of the Drug Medi-Cal Organized Delivery System 1115 Demonstration Waiver on Substance Use Disorder Treatment Access: Evidence from California","volume":"246","author":"Bass","year":"2023","journal-title":"Drug and Alcohol Dependence"},{"issue":"8","key":"2026010812401125400_jhppl12166733C4","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2020.8969","article-title":"Therapies Offered at Residential Addiction Treatment Programs in the United States","volume":"324","author":"Beetham","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"2026010812401125400_jhppl12166733C5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1377\/hlthaff.2020.00378","article-title":"Admission Practices and Cost of Care for Opioid Use Disorder at Residential Addiction Treatment Programs in the US","volume":"40","author":"Beetham","year":"2021","journal-title":"Health Affairs"},{"issue":"16","key":"2026010812401125400_jhppl12166733C6","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1056\/NEJMc2312906","article-title":"Buprenorphine Dispensing After Elimination of the Waiver Requirement","volume":"390","author":"Chua","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"2026010812401125400_jhppl12166733C7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108146","article-title":"A Systematic Review of Patients\u2019 and Providers\u2019 Perspectives of Medications for Treatment of Opioid Use Disorder","volume":"119","author":"Cioe","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"key":"2026010812401125400_jhppl12166733C8","unstructured":"CMS (Centers for Medicare and Medicaid Services). 2015. \u201cSMD # 15\u2013003: New Service Delivery Opportunities for Individuals with a Substance Use Disorder.\u201d July27. https:\/\/www.medicaid.gov\/federal-policy-guidance\/downloads\/SMD15003.pdf."},{"key":"2026010812401125400_jhppl12166733C9","unstructured":"CMS (Centers for Medicare and Medicaid Services). 2017. \u201cSMD # 17\u2013003: RE: Strategies to Address the Opioid Epidemic.\u201d November1. https:\/\/www.medicaid.gov\/federal-policy-guidance\/downloads\/SMD17003.pdf."},{"key":"2026010812401125400_jhppl12166733C10","unstructured":"Cohen, Cathren\n          , H\u00e9ctorHern\u00e1ndez-Delgado, and AlexisRobles-Fradet. 2021. \u201cMedicaid Section 1115 Waivers for Substance Use Disorders: A Review.\u201d National Health Law Program, June8. https:\/\/healthlaw.org\/wp-content\/uploads\/2021\/06\/FINAL_Medicaid-1115-Waivers-for-SUD-updated.pdf."},{"key":"2026010812401125400_jhppl12166733C11","doi-asserted-by":"crossref","DOI":"10.1186\/s13012-021-01182-4","article-title":"Translating Medicaid Policy into Practice: Policy Implementation Strategies from Three US States\u2019 Experiences Enhancing Substance Use Disorder Treatment","volume":"17","author":"Crable","year":"2022","journal-title":"Implementation Science"},{"issue":"4","key":"2026010812401125400_jhppl12166733C12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1215\/03616878-9716740","article-title":"How Do Medicaid Agencies Improve Substance Use Treatment Benefits? Lessons from Three States\u2019 1115 Waiver Experiences","volume":"47","author":"Crable","year":"2022","journal-title":"Journal of Health Politics, Policy and Law"},{"key":"2026010812401125400_jhppl12166733C13","unstructured":"Cunningham, Peter, et al. 2020. \u201cExpanding Access to Addiction Treatment Services Through Section 1115 Waivers for Substance Use Disorders: Experiences from Virginia and Maryland.\u201d Academy Health, April28. https:\/\/academyhealth.org\/sites\/default\/files\/expandingaccesstoaddictiontreatmentthrough1115waivers_april2020.pdf."},{"key":"2026010812401125400_jhppl12166733C14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.drugalcdep.2019.03.031","article-title":"The Effectiveness of Residential Treatment Services for Individuals with Substance Use Disorders: A Systematic Review","volume":"201","author":"de Andrade","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"2026010812401125400_jhppl12166733C15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1176\/appi.ps.201800412","article-title":"Introduction to \u2018Medicaid's Institutions for Mental Diseases (IMD) Exclusion Rule: A Policy Debate\u2019","volume":"70","author":"Dixon","year":"2019","journal-title":"Psychiatric Services"},{"issue":"3","key":"2026010812401125400_jhppl12166733C16","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/1468-0009.12710","article-title":"The Impact of Medicaid Institutions for Mental Disease Exclusion Waivers on the Availability of Substance Abuse Treatment Services and the Varying Effect by Ownership Type","volume":"102","author":"Ge","year":"2024","journal-title":"Milbank Quarterly"},{"issue":"8","key":"2026010812401125400_jhppl12166733C17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.27488","article-title":"Use of Medication for Opioid Use Disorder Among Adults with Past-Year Opioid Use Disorder in the US, 2021","volume":"6","author":"Jones","year":"2023","journal-title":"JAMA Network Open"},{"issue":"7","key":"2026010812401125400_jhppl12166733C18","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.1982","article-title":"Characteristics and Prescribing Patterns of Clinicians Waivered to Prescribe Buprenorphine for Opioid Use Disorder Before and After Release of New Practice Guidelines","volume":"4","author":"Jones","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"5","key":"2026010812401125400_jhppl12166733C19","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1377\/hlthaff.2023.01306","article-title":"Licensure Policies May Help States Ensure Access to Opioid Use Disorder Medication in Specialty Addiction Treatment","volume":"43","author":"Kennedy-Hendricks","year":"2023","journal-title":"Health Affairs"},{"key":"2026010812401125400_jhppl12166733C20","unstructured":"KFF. n.d. \u201cMedicaid Waiver Tracker: Approved and Pending Section 1115 Waivers by State.\u201d Updated August1, 2025. https:\/\/www.kff.org\/medicaid\/issue-brief\/medicaid-waiver-tracker-approved-and-pending-section-1115-waivers-by-state\/."},{"issue":"15","key":"2026010812401125400_jhppl12166733C21","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ajhp\/zxz105","article-title":"Medications for Management of Opioid Use Disorder","volume":"76","author":"Koehl","year":"2019","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"5","key":"2026010812401125400_jhppl12166733C22","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3122\/jabfm.2023.230048R1","article-title":"The End of the X-Waiver: Excitement, Apprehension, and Opportunity","volume":"36","author":"LeFevre","year":"2023","journal-title":"Journal of the American Board of Family Medicine"},{"issue":"11","key":"2026010812401125400_jhppl12166733C23","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1377\/hlthaff.2024.00461","article-title":"Effects of Medicaid Waivers on Use of Medications for Opioid Use Disorder and Nonfatal Overdoses in 17 States","volume":"43","author":"Lindner","year":"2024","journal-title":"Health Affairs"},{"issue":"2","key":"2026010812401125400_jhppl12166733C24","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1377\/hlthaff.2020.00404","article-title":"Institutions for Mental Diseases Medicaid Waivers: Impact on Payments for Substance Use Treatment Facilities","volume":"40","author":"Maclean","year":"2021","journal-title":"Health Affairs"},{"key":"2026010812401125400_jhppl12166733C25","article-title":"Provisional Drug Overdose Death Counts","author":"NCHS (National Center for Health Statistics)","year":"2025"},{"key":"2026010812401125400_jhppl12166733C26","doi-asserted-by":"crossref","DOI":"10.1016\/j.josat.2024.209382","article-title":"Buprenorphine Prescribing and Treatment Accessibility in Response to Regulation Changes due to the COVID-19 Public Health Emergency","volume":"162","author":"Paiva","year":"2024","journal-title":"Journal of Substance Use and Addiction Treatment"},{"key":"2026010812401125400_jhppl12166733C27","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2024.104381","article-title":"Buprenorphine Dispensing Before and after the April 2021 X-Waiver Exemptions: An Interrupted Time Series Analysis","volume":"126","author":"Roy","year":"2024","journal-title":"International Journal of Drug Policy"},{"key":"2026010812401125400_jhppl12166733C28","unstructured":"Saraswathula, Varun\n          . 2023. \u201cMedicaid's Institution for Mental Diseases (IMD) Exclusion.\u201d Congressional Research Service, February25. https:\/\/crsreports.congress.gov\/product\/pdf\/IF\/IF10222."},{"key":"2026010812401125400_jhppl12166733C29","unstructured":"Saunders, Heather\n          , and KathyGifford. 2024. \u201cState Approaches to Addressing the Opioid Epidemic: Findings from a Survey of State Medicaid Programs.\u201d KFF, February6. https:\/\/www.kff.org\/medicaid\/issue-brief\/state-approaches-to-addressing-the-opioid-epidemic-findings-from-a-survey-of-state-medicaid-programs\/."},{"key":"2026010812401125400_jhppl12166733C30","doi-asserted-by":"crossref","DOI":"10.1016\/j.josat.2023.209023","article-title":"Drug Treatment Perspectives and Experiences Among Family and Friends of People Who Use Illicit Opioids: A Mixed Methods Study","volume":"148","author":"Slocum","year":"2023","journal-title":"Journal of Substance Use and Addiction Treatment"},{"issue":"1","key":"2026010812401125400_jhppl12166733C31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1377\/hlthaff.2023.00715","article-title":"Medications for Opioid Use Disorder Increased Among Louisiana Medicaid Enrollees During Policy Reforms, 2018\u201321","volume":"43","author":"Sugarman","year":"2024","journal-title":"Health Affairs"},{"issue":"2","key":"2026010812401125400_jhppl12166733C32","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Network Open"}],"container-title":["Journal of Health Politics, Policy and Law"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/read.dukeupress.edu\/jhppl\/article-pdf\/51\/1\/83\/2355048\/83statchen.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/read.dukeupress.edu\/jhppl\/article-pdf\/51\/1\/83\/2355048\/83statchen.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:40:20Z","timestamp":1767894020000},"score":1,"resource":{"primary":{"URL":"https:\/\/read.dukeupress.edu\/jhppl\/article\/51\/1\/83\/402226\/Section-1115-Substance-Use-Disorder-Waivers"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,1]]},"published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1215\/03616878-12166733","relation":{},"ISSN":["0361-6878","1527-1927"],"issn-type":[{"value":"0361-6878","type":"print"},{"value":"1527-1927","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,2,1]]}}}